Evodiamine.

Evodiamine from Evodia rutaecarpa and berberine from Coptis are combined in classical formulations, and that pairing is why they co-occur so often in the research index. Both are alkaloids with poor oral availability and both are substrates for efflux and hepatic metabolism, so taken together they compete for the same clearance routes. The interaction has been characterised mechanistically rather than in controlled human trials. Anyone stacking two alkaloids should count that overlap rather than assume the effects simply add.

Caffeine is cleared almost entirely by CYP1A2. Rutaecarpine, which travels with evodiamine in any Evodia rutaecarpa extract, induces that enzyme, which means caffeine is cleared faster and its effect at a given dose is blunted. Products that combine an Evodia extract with caffeine for thermogenic purposes are working against themselves on that axis. The direction is well characterised. The size in a person taking a supplement dose is not.

Melatonin undergoes 6-hydroxylation by CYP1A2 before conjugation and excretion. An Evodia extract carrying rutaecarpine speeds that clearance, so the same melatonin dose sits in circulation for less time. Separating the two, or being aware that a thermogenic stack may be quietly shortening a melatonin dose, is the practical read. Mechanistically grounded, not measured in a controlled human study of this pairing.

Evodiamine is a recognised TRPV1 agonist, which is the same receptor capsaicin acts on. Channel opening lets calcium and sodium enter the cell, and that calcium influx is the proximal signal behind the downstream effects reported in cell work. Capsazepine, a TRPV1 antagonist, blocks it, which is why that compound shows up repeatedly alongside evodiamine in the literature index. This describes the receptor mechanism, not an effect measured in people.

Evodiamine has documented hepatotoxic potential at higher exposures, and glutathione conjugation is a standard route for handling reactive metabolites of alkaloids in the liver. Glutathione depletion is the point at which such handling stops keeping up. This is a caution about the compound rather than a reason to combine the two. Anyone using an Evodia extract should count liver load, not assume an antioxidant cancels it.

Work in Chinese medicine journals describes evodiamine-induced hepatotoxicity in animals, framed as a dose-dependent liver effect. Silymarin is the conventional hepatoprotective co-ingredient in botanical formulation. There is no trial showing it offsets evodiamine specifically, so this is formulation logic rather than demonstrated protection. The more useful conclusion is that the liver signal is real enough that the compound is not one to push on dose.

Evodiamine is poorly available orally because of first-pass metabolism and efflux transport. Piperine inhibits CYP3A4 and P-glycoprotein, which raises systemic exposure to compounds handled by those routes. That cuts both ways here: raising exposure to a compound with a documented liver signal is not obviously desirable. The mechanism is well described. Whether the pairing is wanted is a separate judgement.

Evodiamine dissolves poorly in water, which is a large part of why its oral availability is low. A lipid vehicle disperses it and supports micellar uptake in the small intestine. This is why encapsulated and lipid-based delivery systems dominate the formulation literature for this compound. It changes how much gets in, not what it does once there.

Quercetin inhibits several UGT and sulfotransferase reactions and modulates efflux transport, which are the same routes that limit alkaloid exposure. Combined, the two compete for finite conjugation capacity, which can raise circulating levels of either beyond what the doses suggest. This is a general polyphenol-alkaloid interaction rather than something measured for this specific pair. Flagged because it changes exposure, and exposure is where this compound's liver signal lives.